Vicore Pharma Holding AB

The busy week for the idiopathic pulmonary fibrosis (IPF) space has continued apace with the news that Roche is selling off rights to one of the two drugs currently approved for the debilitating and f

PureTech Health’s bid to change the treatment paradigm for idiopathic pulmonary fibrosis (IPF) has been boosted by mid-stage data on its candidate that appears to have overcome the tolerability issues

Sweden's Vicore Pharma can now boast Sanofi as a backer as it kicks off mid-stage trials of its idiopathic pulmonary fibrosis (IPF) candidate, buloxibutid. The French drugmaker has committed to s

With the flow of initial public offerings frustratingly sluggish and a tight financing environment, biopharma companies are looking for advice on other ways to bring in funding capital or explore busi